Indications / Non-small cell lung cancer · Breast cancer · Pancreatic cancer · Colorectal cancer · Acute myeloid leukemia · Chronic myeloid leukemia · Multiple myeloma · Glioblastoma · Glioma · Neuroblastoma · Medulloblastoma · Diffuse midline glioma (DIPG) · Ependymoma · Atypical teratoid rhabdoid tumour (AT/RT) · Childhood acute lymphoblastic leukemia · Ewing sarcoma · Osteosarcoma · Rhabdomyosarcoma
Breast cancer
HR+/HER2-, HER2-low and TNBC: CDK4/6, oral SERDs, PI3K pathway and TROP2 ADCs.
SITC Annual Meeting 2026
4–8 Nov 2026, Phoenix · Journal for ImmunoTherapy of Cancer 14 (Suppl 2 and 3), open access
1,109 regular and 19 late-breaking abstracts are in Crossref as open-access JITC supplement records (CC BY-NC); the supplement may still be filling in.
Indexed in Crossref
54 abstracts matching breast cancer from the meeting's journal supplement, fetched live from Crossref 2026-11-12 09:57 UTC. This is a keyword search, not the complete abstract book.
- 695Spatial immunoprofiling reveals NACC1-driven immunosuppressive tumor-infiltrating lymphocytes in triple-negative breast cancerDuminduni Y Hewa Angappulige, Jianxun Jim Song
- 838ETV6 rearrangements impair T cell infiltration via activating β-Catenin signaling in triple-negative breast cancerXiaosong Wang, Yue Wang, Binfeng Lu
- 595
- 1037
- 1063Fisetin enhances HSV-1 VC2-GMCSF-mediated antitumor activity in triple-negative breast cancer modelsLeila Rahimian, Reza Ghavimi, Jean C Chamcheu, Konstantin G Kousoulas
- 1107Elevated LSD1 expression is associated with stromal fibronectin enrichment in triple-negative breast cancerDong Yeul Lee, Hui Xin Lau, Jian Zhou Cui, Jabed Iqbal
- 584Enabling CAR-T and macrophage-based therapies in triple-negative breast cancer through bacterial and epigenetic primingRakesh Kumar, Vanessa D Vazhappilly, Hannah Martin, Jianxun Jim Song
- 726Soluble HVEM is associated with pathological complete response in triple-negative breast cancerBernardo Leon Rapoport, Daniel van Tonder, Ronald Anderson, Teresa Smit et al.
- 392Lymphangiogenenic triple negative breast cancer tumors respond better to TGFb and checkpoint blockade due to matrix softening and myeloid, NK and NK T cell recruitment and survivalCamryn Garza, Peyman Hosseinchi, Melody A Swartz
- 33Novel plasma protein biomarkers associated with pathological complete response in triple-negative breast cancer using a high-throughput proximity extension assayBernardo Leon Rapoport, Teresa Smit, Ronald Anderson, Theresa M Rossouw et al.
- 610Enhancing response in MHC-I low triple negative breast cancer with diacylglycerol kinase α/ζ inhibitors and STING activationJacey L Marshall, Paula I Gonzalez-Ericsson, Neil C Chada, P Brent Ferrell et al.
- 370Pathological complete response and immune-related toxicity outcomes with neoadjuvant pembrolizumab-based chemoimmunotherapy in triple-negative breast cancer: a real world Indian experienceSakina Mankada, Krishna Ratanchandani, Vaishnavi Joshi, Sai Vivek Velukuru et al.
- 1101FASN-driven lipid metabolism establishes a post-translational immunometabolic checkpoint that suppresses antigen presentation and promotes immune escape in triple-negative breast cancerMyung Soo Ko, Henry Withers, Glenn Simmons, Jason McCormick et al.
- 228Anti-HER2 CAR-B cells exhibit robust anti-tumor efficacy in vivo in mouse models of HER2 + breast cancerLucia Sereni, Marta Freschi, Silvia Rizzato, Giada Zambonini et al.
- 176Bi-paratopic B7-H3-CAR-T cells to treat metastatic triple negative breast cancerAshlyn T Merce, Alexander J Armstrong, Sae Nishiguchi, Graziella van der Plancke et al.
- 1143Obesity promotes interferon-driven regulatory T-cell activation and CD8 T-cell exhaustion in triple-negative breast cancerAndrew Liu, Yaohua Ma, Roberto A Leon-Ferre, David Zahrieh et al.
- 142DCE-MRI radiogenomics predicts immune microenvironment subtypes and neoadjuvant chemotherapy response in HR + /HER2 − breast cancerRuiliang Chen, Yushuai Yu, Chuangui Song
- 514Initial clinical results from START-002: a phase 1b/2 study of invikafusp alfa, a first-in-class dual T-cell agonist, in combination with sacituzumab govitecan in triple-negative or HR + /HER2 - mBCSteven J Isakoff, Anastasia Martynova, Margaret E Gatti-Mays, Nathalie LeVasseur et al.
- 471Dendritic cell states and SPP1 + macrophages refine patient selection for combined HER2-targeted and immune checkpoint therapy (DTP Clinical Trial) in HER2-enriched early breast cancerMailin Li, Jenying Deng, Xen Ping Hoi, Junjun Zheng et al.
- 342Adoptive PD1 + tumor-infiltrating lymphocyte therapy for metastatic TNBCAlejandro Ramírez-Chacón, Manel Juan, Europa Gonzalez Navarro
- 470Validation and refinement of a kinome-based gene expression signature (ges) for predicting immune infiltration and prognosis in Indian TNBC cohortNavrinder Kaur, Ayushmaan Srivastava, Ravi Kant Singh
- 853Activation of antitumor T cell and antibody responses against 4T1 carcinoma antigens by reprogramming myeloid cells with TLR agonists in a TNBC modelEkaterina Ushakova, Ekaterina Lebedeva, Alexey Pichugin, Ravshan Ataullakhanov
- 141
- 15Predicting immunotherapy response ex vivo : clinical validation of the E-slice assay in TNBC patients in a prospective clinical studyViridiana Leyva-Aranda, Clinton Yam, Reece Kang, Nourhan Abdelfattah et al.
- 679Novel 4-thiazolidinone derivative Les-4367 synergizes with trastuzumab and pertuzumab to suppress immune evasion markers in HER2-positive gastric cancerAnna Bielawska, Agnieszka Gornowicz, Magdalena Podolak, Wojciech Szymanowski et al.
- 680Anti-HER2 antibody trastuzumab potentiates antitumor and immunomodulatory activity of the novel heterocyclic compound LES-6400 in gastric cancerKrzysztof Bielawski, Piotr Roszczenko, Olga Klaudia Szewczyk-Roszczenko, Agnieszka Gornowicz et al.
- 837Targeting a CD36-dependent macrophage immunometabolic program enhances PARP inhibitor response in BRCA-associated TNBCCarlos Wagner S Wanderley, Daniel E Michaud, Kiran Kurmi, Adam Nelson et al.
- 925Tumor-associated macrophage-targeting nanoantioxidant for combating immune exhaustion in breast cancersErica Guelfi, EunHye Kimx, Katelyn Wahl, DaeYong Lee
- 806Chemotherapy class determines the magnitude and mechanism of IL-1α release from breast cancer cellsMaryam Ayazi, Kay Hänggi, Brian Ruffell
- 694The role of B cell specific MHC II antigen presentation in breast cancerChaitali Bhadiadra, Jian Gao, Chunru Lin, Liuqing Yang
- 24
- 66
- 400Proinflammatory and immune checkpoint responses in bystander tumor cells in an in vitro breast cancer modelFiorella Calderón-Milán, Javier Mora, Lucia Figueroa-Protti
- 1169H2B variants drive immune evasion in aggressive breast cancerDominique Monroe, Hejer Dhahri, Youssef Hegazy, Leah Meyer et al.
- 1033
- 81Spatial links between ADC target expression, tumor metabolism and immunotherapyrelevant heterogeneity in breast cancerQanber Raza, Nick Zabinyakov, Liang Lim, James Mansfield et al.
- 1141Spatial immune profiling across the lobular breast cancer continuum reveals progressive immune exclusion from precursor lesion to invasive diseaseJessica Linak, Venkatesh Rajamanickam, Jason Schlumbohm, Sasha E Stanton
- 1134Targeting HO-1 + macrophages to remodel the immunosuppressive tumor microenvironment in breast cancer liver metastasisAlexis A Hill, Megan Thomas, Alex Chang, Lauren M McCue et al.
- 293Degenerate TCR recognition expands therapeutic targeting of recurrent HER2 neoantigens in NSCLCAmanda Montoya, Hui Nie, Peixin Jiang, Jared K Slone et al.
- 1020Concordance between chemical and virtual staining for nuclear, tumor, and immune-cell quantification using halo in breast cancer tissueMegan Rothney, Nerissa Lien, Rochelle Wagner, Zhensong Wei et al.
- 261Inference of TCR antigen specificity from CDR3 sequences in a breast cancer malignant pleural effusion: a case studyVera S Donnenberg, Patrick L Wagner, David L Bartlett, Wenjing Pan et al.
- 812Therapeutic induction of tertiary lymphoid structures (TLS) by locoregional hetIL-15 drives durable anti-tumor immunity in murine breast cancer modelsDimitrios Stellas, Sevasti Karaliota, Laura Basel, Katherine Goldfarbmuren et al.
- 461Myeloid—CD8 + T cell interactions and lymphocyte activation mediate response to checkpoint inhibition in metastatic breast cancerEdgar Gonzalez, Jesse Kreger, Yingtong Liu, Xiaojun Wui et al.
- 1160Exposing targetable mediators of immune suppression in breast cancer liver metastasisAngelica D Phan, Amal T Elhaw, Thomas M Hintelmann, Alexis A Hill et al.
- 212Targeting tumor-associated macrophages with CAR-monocytes as a first-in-class approach for cellular therapy in breast cancerDaniel E Michaud, Adam Nelson, Mubin Tarannum, Alexander P Gottlieb et al.
- 764Harnessing natural killer cells to exploit weaknesses in breast cancerLiam Neil, Aleen Al Halawani, Tirta Djajawi, Chamikara Dushmantha Kaluthara Liyanage et al.
- 1118Characterization of the impact of metabolic syndrome on immunity and the progression of HR + breast cancerLeire Arrizabalaga, Pietro Mancuso, Belen Picatoste, Lucie Yammine et al.
- 731Γδ T cell depletion improves susceptibility to CDK4/6 inhibitors in a mouse model of HR + breast cancerLukas Bolini Goncalves, Manuel Beltrán Visiedo, Abdelrahman Ghazal, Claudia Galassi et al.
- 1114Orally bioavailable small-molecule RXFP1 agonist TRND8394 potentiates immunotherapy in breast cancer modelsAlexander I Agoulnik, Omar J Dominguez, Christian Castellanos Botero, Camila Batiz Ortiz et al.
- 707Microbial-derived isoallolithocholic acid attenuates obesity-driven breast cancer through enhanced CD8 + T cell-mediated anti-tumor immunityNaveed Pervaiz, Sandesh J Marathe, Tahliyah S Mims, Adam S Wilson et al.
- 1170Spatial transcriptomics identifies immune heterogeneity in estrogen receptor positive postpartum breast cancerVidya P Nimbalkar, Snijesh VP, Anjaney J Pandey, Apoorva D Mavatkar et al.
- 277First-in-human clinical trial for breast cancer leptomeningeal disease induces adaptive immunity and transcriptomic immune remodelling in the cerebral spinal fluidYolanda Pina, Vincent Law, Kamran Ahmed, Piteo Cecily et al.
- 887Multi-modal analysis of breast cancer biopsies before and after T-DXd and Sac-Gov treatment reveals inflamed tumor status as a major correlate of sensitivity to Topo-I ADCsMichael A Smith, Keith H Jansson, Anoek Zomer, Mina Khoshdeli et al.
- 657Entinostat, a class I HDAC inhibitor, upregulates lncRNA Malat1 , induces G0/G1 cell cycle arrest, and promotes migration and invasion in breast tumor cell linesLori Khatchaturian, Aaron G Baugh, Cheol Park, Yingtong Liu et al.